The HDV system for weight loss can be manufactured for everything from oral capsules to additives to food and beverage products. Being able to move forward with this level of patent protection is very important to our development and commercial strategy.
Cleveland, Ohio (PRWEB) March 06, 2014
Diasome Pharmaceuticals, Inc. (http://www.diasome.com) has received notice from its licensor, SDG, Inc., that SDG has received a notice of allowance for its novel weight loss nanotechnology patent application. This patent, entitled “Orally Bioavailable Lipid Constructs,” covers composition of matter claims related to the use of the Company’s proprietary oral Hepatocyte Directed Vesicles (“HDV”) as a weight loss compound. HDV is a 20-50 nanometer drug delivery system that is designed to target drugs and nutraceuticals to hepatocytes, the liver’s metabolic cells.
Diasome Pharmaceuticals has received a worldwide, exclusive license to this technology from SDG, along with technology rights to SDG’s platform of hepatic (liver) targeted injectable and oral therapies for diabetes and obesity. Diasome’s technologies have received more than $40 million in research and development funding over their history, and the Company has multiple Phase-2 stage human clinical candidates for metabolic conditions in its pipeline.
“We are very pleased with the notice of allowance for this novel weight loss technology,” said Robert Geho, Diasome’s Chief Executive Officer. “The HDV system for weight loss can be manufactured for everything from oral capsules to additives to food and beverage products. Being able to move forward with this level of patent protection is very important to our development and commercial strategy.”
About Diasome Pharmaceuticals, Inc.
Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity.
Diasome’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle, or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. It is generally recognized by diabetologists that the currently available forms of injected insulin used by all Type 1 diabetic patients and a significant percentage of people with Type 2 diabetes do not function in the body in the same way as naturally produced insulin. Because insulin tells the body when and how to store glucose, the ideal insulin therapy would function as closely to normal insulin as possible. Diasome’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by, for the first time, enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells.